Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ophthotech Corp    OPHT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

OPHTHOTECH CORP. : Submission of Matters to a Vote of Security Holders (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/22/2017 | 10:26pm CEST

Item 5.07. Submission of Matters to a Vote of Security Holders.

Ophthotech held its Annual Meeting of Stockholders on May 19, 2017. The following is a summary of the matters voted on at that meeting.

(a) Ophthotech's stockholders elected Michael Ross, Ph.D. and Glenn P. Sblendorio as Class I directors to serve until the 2020 Annual Meeting of Stockholders, each such director to hold office until his successor has been duly elected and qualified. The results of the stockholders' vote with respect to the election of such Class I directors were as follows:


                                                 Broker
                         For       Withheld    Non-Votes

Michael Ross, Ph.D. 16,330,286 819,537 11,361,105 Glenn P. Sblendorio 14,974,194 2,175,629 11,361,105

(b) Ophthotech's stockholders approved a non-binding, advisory proposal on the compensation of Ophthotech's named executive officers. The results of the stockholders' vote with respect to such matter were as follows:

                                     Broker
   For        Against    Abstain   Non-Votes
10,982,939   6,109,509    57,375   11,361,105


(c) Ophthotech's stockholders ratified the selection of Ernst & Young LLP as Ophthotech's independent registered public accounting firm for the current fiscal year. The results of the stockholders' vote with respect to such matter were as follows:

                                  Broker
   For       Against   Abstain   Non-Votes
27,542,577   755,300   213,051           0





                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on OPHTHOTECH CORP
05/22 OPHTHOTECH CORP. : Submission of Matters to a Vote of Security Holders (form 8-K..
05/16 NEWMAN FERRARA LLP : Announces Corporate Governance Investigation of Ophthotech ..
05/04 OPHTHOTECH : Announces Leadership Transition Effective July 1, 2017
05/03 OPHTHOTECH : Management's Discussion and Analysis of Financial Condition and Res..
05/03 OPHTHOTECH : reports 1Q loss
05/03 OPHTHOTECH CORPORATION (NASDAQ : OPHT) Files An 8-K Results of Operations and Fi..
05/03 OPHTHOTECH CORP. : Results of Operations and Financial Condition, Financial Stat..
05/03 OPHTHOTECH : Reports First Quarter 2017 Financial and Operating Results
05/03 OPHTHOTECH CORP : Investor Network: Ophthotech Corp. to Host Earnings Call
04/26 OPHTHOTECH CORPORATION : to Report First Quarter 2017 Financial Results and Host..
More news
Sector news : Bio Therapeutic Drugs
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
05/03 Ophthotech reports Q1 results
05/03 Ophthotech's (OPHT) CEO David Guyer on Q1 2017 Results - Earnings Call Transc..
05/03 Ophthotech beats by $0.12, beats on revenue
04/05 A Quick Evaluation Of Nektar Therapeutics' PEGylation Platform
03/24 After Hours Gainers / Losers
Advertisement
Financials ($)
Sales 2017 3,17 M
EBIT 2017 -143 M
Net income 2017 -142 M
Finance 2017 41,3 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 13,4x
EV / Sales 2018 -1,76x
Capitalization 83,9 M
More Financials
Chart OPHTHOTECH CORP
Duration : Period :
Ophthotech Corp Technical Analysis Chart | OPHT | US6837451037 | 4-Traders
Full-screen chart
Technical analysis trends OPHTHOTECH CORP
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Average target price 4,00 $
Spread / Average Target 71%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David R. Guyer Chairman & Chief Executive Officer
Glenn P. Sblendorio President
Keith Westby Chief Operating Officer & Senior Vice President
David F. Carroll Chief Financial Officer, Treasurer & Senior VP
Axel Bolte Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
OPHTHOTECH CORP-51.55%84
AMGEN, INC.6.02%113 994
CELGENE CORPORATION0.89%91 185
GILEAD SCIENCES, INC.-9.93%84 284
REGENERON PHARMACEUTIC..23.99%48 380
ACTELION LTD24.38%30 559
More Results